Quince Therapeutics, Inc.
QNCX
$34.04
$1.635.03%
NASDAQ
| 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 4.27M | 3.64M | 3.28M | 3.34M | 4.79M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 11.11M | 16.24M | 11.36M | 9.90M | 12.93M |
| Operating Income | -11.11M | -16.24M | -11.36M | -9.90M | -12.93M |
| Income Before Tax | 30.57M | -36.31M | -13.49M | -15.98M | -14.98M |
| Income Tax Expenses | -5.34M | 3.15M | -46.00K | 67.00K | 47.00K |
| Earnings from Continuing Operations | 35.91M | -39.46M | -13.44M | -16.05M | -15.03M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 35.91M | -39.46M | -13.44M | -16.05M | -15.03M |
| EBIT | -11.11M | -16.24M | -11.36M | -9.90M | -12.93M |
| EBITDA | -11.08M | -16.20M | -11.33M | -9.86M | -12.90M |
| EPS Basic | 71.91 | -141.72 | -49.83 | -68.75 | -68.41 |
| Normalized Basic EPS | 29.99 | -73.28 | -25.19 | -40.03 | -35.89 |
| EPS Diluted | 57.58 | -141.72 | -49.83 | -68.75 | -68.41 |
| Normalized Diluted EPS | 29.76 | -73.28 | -25.19 | -40.03 | -35.89 |
| Average Basic Shares Outstanding | 456.00K | 278.40K | 269.80K | 233.40K | 219.70K |
| Average Diluted Shares Outstanding | 459.50K | 278.40K | 269.80K | 233.40K | 219.70K |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |